Real-World Results On Ibrutinib In Relapsed/Refractory Cll: A 21-Month Follow-Up Of 95 Swedish Patients Treated In A Compassionate Use Program

Background: Ibrutinib is current standard of care for patients with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) based on phase 3 clinical trials. There is often a discrepancy between data obtained in clinical trials with strict inclusion criteria and those later obtained in routine health care. We have previously reported the 10-month follow-up of real-world results on ibrutinib in consecutive Swedish CLL patients treated in a compassionate use program (CUP) (Winqvist et al., 2016). Here we present follow-up data at 21-month follow-up with extended PFS, OS and safety.